Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Aluminum Adjuvant-Controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E. Coli) in Chinese Males Aged 18 to 45 Years

NCT06866574 is registered in ClinicalTrials.gov with Xiamen University as lead sponsor.

NCT NCT06866574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06866574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Aluminum Adjuvant-Controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E. Coli) in Chinese Males Aged 18 to 45 Years
Lead sponsor
Xiamen University
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 11, 2025
Completion date
September 30, 2031
Enrollment
9,300 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, anal intraepithelial neoplasia, genital warts, penile/perianal/perineal cancer, penile/perineal /perianal intraepithelial neoplasia